March 28, 2025 06:53 AM EDT

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Ayisha Sharma

News Reporter

Merck KGaA is spending $85 million to tap global commercialization rights to pimicotinib, a candidate for non-malignant tumors that it licensed from China’s Abbisko Therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Sanofi continues its bet on R&D by poaching GSK’s head of development

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Mer­ck KGaA pays Ab­bisko $85M for full com­mer­cial rights to be­nign tu­mor drug

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

RFK Jr. has long crit­i­cized drug ads. He just slashed the FDA of­fice that reg­u­lates them

‘It’ll be a chal­lenge’: BIO chief Crow­ley ad­dress­es seis­mic FDA over­haul

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

Sanofi con­tin­ues its bet on R&D by poach­ing GSK’s head of de­vel­op­ment

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

Merck KGaA pays Abbisko $85M for full commercial rights to benign tumor drug

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Sanofi continues its bet on R&D by poaching GSK’s head of development

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO